Gilead Sciences in talks with pharma companies in Pakistan, India to start remdesivir production

Published May 6, 2020
Vials of experimental coronavirus  treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US. — Reuters/File
Vials of experimental coronavirus treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US. — Reuters/File

US pharmaceutical company Gilead Sciences on Tuesday said that it was in talks with drug companies in Pakistan and India to start remdesivir production.

Remdesivir is an experimental antiviral drug used to treat patients with the coronavirus and was recently approved by the US Food and Drug Administration (FDA).

Last month, Gilead said the drug had helped improve outcomes for patients with Covid-19, the disease caused by the coronavirus, and provided data suggesting it worked better when given earlier in the course of infection.

According to a statement on its website, Gilead Sciences "is negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing countries. Gilead will provide appropriate technology transfers to facilitate this production".

The statement adds that the company's goal "is to make remdesivir both accessible and affordable to governments and patients around the world" and it plans to continue the production of the drug for "Europe, Asia and the developing world through at least 2022".

'Significant, positive effect in diminishing time to recovery'

A clinical trial of the drug remdesivir in the United States showed that patients recovered about 30 per cent faster than those on a placebo, in the first proof of successful treatment against the new disease.

“The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery,” Anthony Fauci, the top US epidemiologist who oversaw the study, told reporters on Friday.

Fauci likened the finding to the first retrovirals that worked, albeit with modest success, against HIV in the 1980s.

However, remdesivir failed in trials against the Ebola virus and a smaller study, released last week by the World Health Organisation, found limited effects among patients in Wuhan, China, where the illness was first detected in December.

Opinion

A crisis of trust?

A crisis of trust?

Most damaging fallout of the constant demonisation of opponents by political leaders is erosion of public trust in politicians.

Editorial

An unseemly dispute
08 Aug, 2022

An unseemly dispute

THERE is clarity, but perhaps not of the kind that Chief Justice of Pakistan Umar Ata Bandial hoped to achieve when...
Unfair on taxpayers
Updated 08 Aug, 2022

Unfair on taxpayers

Unfair move has drawn valid criticism as it coincides with drastic increase in income tax on salaried people and corporates.
Polio nightmare
08 Aug, 2022

Polio nightmare

AS if the resurgence of polio in southern KP were not enough, officials and international monitoring bodies must now...
Political stunt
Updated 07 Aug, 2022

Political stunt

The former PM is attempting to make a very expensive point with his decision to contest all 9 NA seats going up for by-election.
Monsoon emergency
07 Aug, 2022

Monsoon emergency

AS another wet weather system has entered Pakistan, and the federal government has declared a “monsoon...
Taliban’s denial
07 Aug, 2022

Taliban’s denial

THE Afghan Taliban’s recent statement denying any knowledge of the now deceased Al Qaeda chief Ayman...